Simon Read
Director · Dianthus Therapeutics, Inc. /DE/
IndividualSelling only11 10b5-1 trades
- 2026
- Aug 19, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Simon Read files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Marino Garcia - $27.96M in DNTH purchases and sales in the last 12 months
- Simrat Randhawa - $15.00M in DNTH purchases and sales in the last 12 months
- Ryan Savitz - $14.29M in DNTH purchases and sales in the last 12 months
- Edward Carr - $5.59M in DNTH purchases and sales in the last 12 months
- Adam M. Veness - $4.63M in DNTH purchases and sales in the last 12 months
- Paula Soteropoulos - $2.25M in DNTH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Simon Read?
Simon Read is a corporate insider, tracked as Director of Dianthus Therapeutics, Inc. /DE/ (DNTH). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Simon Read submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Simon Read been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($631K) across all tracked filings.
